Home > Haematology > ASH 2019 > Late-Breaking Abstracts > MRD assessment to guide pre-emptive treatment decisions

MRD assessment to guide pre-emptive treatment decisions

Presented By
Prof. Uwe Platzbecker, University Hospital Carl Gustav Carus, Germany
Conference
10:22:54pm> hello nurse from conference
Trial
Phase 2, RELAZA2
The phase 2 RELAZA2 trial evaluated the role of hypomethylation agent azacitidine in minimal residual disease (MRD)-guided pre-emptive therapy to prevent or delay relapse in patients with myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) after chemotherapy and allogenic stem cell transplantation. The authors concluded that MRD monitoring can identify patients who are likely to relapse, and MRD-guided maintenance with azacitidine could be an effective strategy to delay relapse. Prof. Uwe Platzbecker (University Hospital Carl Gustav Carus, Germany) presented the prospective study, which aimed to determine whether MRD-guided pre-emptive treatment with azacitidine could prevent relapse [1]. The researchers screened 198 patients with advanced MDS (n=26) or AML (n=172). Of these patients, 30% tested positive for MRD during the 24-month screening period.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on